Daiichi Sankyo Trials Of Liver-Cancer Drug Get Go-Ahead By Safety Panel
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's Japan trial of ArQule's tivantinib as a treatment for liver cancers got the go-ahead from a safety committee to continue testing the drug at a lower dose because of serious side-effect concerns.